16 known cases. View patent page →
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Jazz sued Alkem in a Xyrem-related ANDA action; the complaint asserted the '426 patent plus other patents. The case was voluntarily dismissed, with a Rule 41(a)(1)(A)(i) order signed Oct. 5, 2023, and the case terminated.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.
Consolidated D.N.J. Xyrem action in which the '306 patent was folded in and construed in the court's Markman decision. Terminated by Amneal settlement on Oct 15, 2018.
The '306 patent was asserted; Roxane moved to dismiss the '306 claims on §101 subject-matter eligibility, which the court administratively terminated and stayed discovery on pending IPR. The case was consolidated with Roxane's '302 case on Mar 24, 2016 and settled in April 2017.
Resolved by a stipulation/consent judgment of dismissal. Wockhardt admitted the ANDA filing was a technical act of infringement of the asserted patents, expressly including 8,772,306, and was enjoined except as permitted by the April 18, 2016 license agreement.
The '306 patent was asserted against Lupin. The case settled on June 12, 2018, as described in antitrust complaints.
Complaint expressly lists the '306 patent among the patents-in-suit. Status not confirmed.
Xyrem/Xywav action against Teva Pharmaceuticals. Status not confirmed.
Most recent confirmed '306-family action. Status not confirmed.
Second Tris Pharma complaint filed after Tris's Jan 2026 notices of 505(b)(2) NDAs for Xyrem/Xywav generics. The narrative lists it among '306-family actions, though only 2:26-cv-01739 is expressly noted as identifying the '306 patent.
Case number appears in Google Patents' litigation record linked to U.S. 8,772,306; parties and filing dates unverified in the narrative.
Petition by Par Pharmaceutical, Inc. challenging the '306 patent. The Board did not institute review on the merits, decision Apr 12, 2016.
Petition by Ranbaxy, Inc. challenging the '306 patent. The proceeding settled per Google Patents.
Petition by Amneal Pharmaceuticals LLC challenging the '306 patent. The Board did not institute review on the merits; cited as Amneal Pharms. LLC v. Jazz Pharms. Ireland Ltd., 2016 WL 5222883 (PTAB July 28, 2016).
Collateral False Claims Act case concerning the '306 patent. Relator alleges Jazz defrauded the PTO in obtaining the '306 patent; the United States and several states declined to intervene, an amended complaint was filed Sept 1, 2024, and Jazz's motion to dismiss was filed Dec 2, 2024, with oral argument Apr 2, 2025.